Valnemulin restores colistin sensitivity against multidrug-resistant gram-negative pathogens

Colistin is one of the last-resort antibiotics in treating infections caused by multidrug-resistant (MDR) pathogens. Unfortunately, the emergence of colistin-resistant gram-negative strains limit its clinical application. Here, we identify an FDA-approved drug, valnemulin (Val), exhibit a synergistic effect with colistin in eradicating both colistin-resistant and colistin-susceptible gram-negative pathogens both in vitro and in the mouse infection model. Furthermore, Val acts synergistically with colistin in eliminating intracellular bacteria in vitro. Functional studies and transcriptional analysis confirm that the combinational use of Val and colistin could cause membrane permeabilization, proton motive force dissipation, reduction in intracellular ATP level, and suppression in bacterial motility, which result in bacterial membrane disruption and finally cell death. Our findings reveal the potential of Val as a colistin adjuvant to combat MDR bacterial pathogens and treat recalcitrant infections.

Authors

Institutions

Publication Details

Journal
Communications Biology
Published
2024-09-12
DOI
https://doi.org/10.1038/s42003-024-06805-2
Citations
10
Primary Topic
Antibiotic Resistance in Bacteria
Type
article
Field-Weighted Citation Impact
1.70

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Valnemulin restores colistin sensitivity against multidrug-resistant gram-negative pathogens

Yunbing Li, Chenjie Zhang, Yuanyuan Li, Guang-Fen Zhang et al.
10 citations
Communications Biology
Antibiotic Resistance in Bacteria
1.70
article

Valnemulin restores colistin sensitivity against multidrug-resistant gram-negative pathogens

Yunbing Li, Chenjie Zhang, Yuanyuan Li, Guang-Fen Zhang, Ning Dong, Yuan Zhang, Chunli Li, Chen Xu, Lingman Ma, Xiangkun Zeng
article en
10 citations

Abstract

Colistin is one of the last-resort antibiotics in treating infections caused by multidrug-resistant (MDR) pathogens. Unfortunately, the emergence of colistin-resistant gram-negative strains limit its clinical application. Here, we identify an FDA-approved drug, valnemulin (Val), exhibit a synergistic effect with colistin in eradicating both colistin-resistant and colistin-susceptible gram-negative pathogens both in vitro and in the mouse infection model. Furthermore, Val acts synergistically with colistin in eliminating intracellular bacteria in vitro. Functional studies and transcriptional analysis confirm that the combinational use of Val and colistin could cause membrane permeabilization, proton motive force dissipation, reduction in intracellular ATP level, and suppression in bacterial motility, which result in bacterial membrane disruption and finally cell death. Our findings reveal the potential of Val as a colistin adjuvant to combat MDR bacterial pathogens and treat recalcitrant infections.

Communications BiologyVol. 7(1)
Jiangsu University (CN), China Pharmaceutical University (CN), Soochow University (CN), Second Affiliated Hospital of Zhejiang University (CN), Chongqing Medical University (CN)
National Natural Science Foundation of China, Jiangsu University, China Postdoctoral Science Foundation, Government of Jiangsu Province, Natural Science Foundation of Jiangsu Province, Priority Academic Program Development of Jiangsu Higher Education Institutions, Senior Talent Foundation of Jiangsu University, Postdoctoral Research Foundation of China
Zero hunger
Openalex Percentile: Top 15%
Antibiotic Resistance in Bacteria
1.70
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.